Market Research Logo

Contact Lenses - Medical Devices Pipeline Assessment, 2017

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Contact Lenses Overview
3 Products under Development
3.1 Contact Lenses - Pipeline Products by Stage of Development
3.2 Contact Lenses - Pipeline Products by Segment
3.3 Contact Lenses - Pipeline Products by Territory
3.4 Contact Lenses - Pipeline Products by Regulatory Path
3.5 Contact Lenses - Pipeline Products by Estimated Approval Date
3.6 Contact Lenses - Ongoing Clinical Trials
4 Contact Lenses - Pipeline Products under Development by Companies
4.1 Contact Lenses Companies - Pipeline Products by Stage of Development
4.2 Contact Lenses - Pipeline Products by Stage of Development
5 Contact Lenses Companies and Product Overview
5.1 Aeon Astron Corporation Company Overview
5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.2 Alcon Laboratories Inc Company Overview
5.2.1 Alcon Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview
5.3 Apeliotus Ophthalmics (Inactive) Company Overview
5.3.1 Apeliotus Ophthalmics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.4 Auburn University Company Overview
5.4.1 Auburn University Pipeline Products & Ongoing Clinical Trials Overview
5.5 Axcelon Biopolymers Corp. Company Overview
5.5.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview
5.6 Bar-Ilan University Company Overview
5.6.1 Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview
5.7 Bausch & Lomb Inc Company Overview
5.7.1 Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview
5.8 Children's Hospital Boston Company Overview
5.8.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
5.9 CooperVision Inc Company Overview
5.9.1 CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview
5.10 EP Global Communications, Inc. Company Overview
5.10.1 EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.11 Euclid Systems Corp Company Overview
5.11.1 Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview
5.12 e-Vision Medical Devices, Inc. Company Overview
5.12.1 e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.13 Eyenovations Company Overview
5.13.1 Eyenovations Pipeline Products & Ongoing Clinical Trials Overview
5.14 EyeYon Medical Company Overview
5.14.1 EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview
5.15 Imperial College London Company Overview
5.15.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
5.16 Johnson & Johnson Vision Care Inc Company Overview
5.16.1 Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview
5.17 Massachusetts Eye and Ear Infirmary Company Overview
5.17.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview
5.18 Novartis AG Company Overview
5.18.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
5.19 Ocular Dynamics, LLC Company Overview
5.19.1 Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.20 Ocutec Ltd Company Overview
5.20.1 Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.21 Presbia Plc Company Overview
5.21.1 Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview
5.22 RetMap Inc Company Overview
5.22.1 RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview
5.23 Stanford University Company Overview
5.23.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview
5.24 SynergEyes Inc Company Overview
5.24.1 SynergEyes Inc Pipeline Products & Ongoing Clinical Trials Overview
5.25 The Hong Kong University of Science and Technology Company Overview
5.25.1 The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview
5.26 The University of New South Wales Company Overview
5.26.1 The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview
5.27 UltraVision CLPL Company Overview
5.27.1 UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview
5.28 University of California San Diego Company Overview
5.28.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
5.29 University of Florida Company Overview
5.29.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview
5.30 University of Valencia Company Overview
5.30.1 University of Valencia Pipeline Products & Ongoing Clinical Trials Overview
5.31 University of Washington Company Overview
5.31.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview
5.32 Valeant Pharmaceuticals International Inc Company Overview
5.32.1 Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview
5.33 Visioneering Technologies Inc Company Overview
5.33.1 Visioneering Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.34 VISTAKON Pharmaceuticals LLC Company Overview
5.34.1 VISTAKON Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview
5.35 Yolia Health Company Overview
5.35.1 Yolia Health Pipeline Products & Ongoing Clinical Trials Overview
6 Contact Lenses- Recent Developments
6.1 Jul 13, 2017: Visioneering Technologies Appoints Michelle Kirst as Territory Manager for New Jersey
6.2 Jul 11, 2017: Visioneering Technologies Appoints Ron Makelke as Territory Manager for San Francisco
6.3 Jul 06, 2017: Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX Contact Lenses
6.4 Jul 06, 2017: Visioneering Technologies Appoints Carol Baez as Executive Territory Manager for Orange County/San Diego
6.5 Jun 29, 2017: Visioneering Technologies Announces Connie Stewart as Territory Manager, Los Angeles
6.6 Jun 27, 2017: Visioneering Technologies Names Mark Rapoport as New CFO
6.7 Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International
6.8 Jun 20, 2017: Visioneering Technologies Announces Dave Halverson as Territory Manager in Southern California
6.9 Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications
6.10 Jun 19, 2017: John Paulson Joins Valeant Board Of Directors
6.11 Jun 13, 2017: KAMRA Corneal Inlay Helps College Administrator End Her Blurry Near Vision and Dependence on Reading Glasses
6.12 Jun 10, 2017: Three-Year Study Indicates Pioneering Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59%
6.13 Jun 10, 2017: Three-year study says new contact lens therapy slows myopia progression in children by 59 percent
6.14 Jun 01, 2017: The Cooper Companies Announces Second Quarter 2017 Results
6.15 Jun 01, 2017: The Cooper Companies Announces Second Quarter 2017 Results
6.16 May 30, 2017: The German Court has Granted a Preliminary Injunction in Favour of VSY Biotechnology BV and Against Carl Zeiss Meditec
6.17 May 23, 2017: Presbia Provides Update on US Staged Pivotal Clinical Trial For Flexivue Microlens
6.18 May 22, 2017: Bausch + Lomb Introduces renu Advanced Formula Multi-Purpose Solution
6.19 May 11, 2017: Hoya Reports Fourth Quarter and Full-Year Financial Results
6.20 May 10, 2017: Carl Zeiss Meditec accelerates growth in the first six months of 2016/17
6.21 May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range
6.22 May 08, 2017: ZEISS Appoints New Fellow
6.23 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy
6.24 May 05, 2017: Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership
6.25 May 03, 2017: Presbia to Participate in the 2017 ASCRS Symposium & Congress in Los Angeles, California
6.26 May 02, 2017: KAMRA Corneal Inlay Utilizes Camera Technology to Sharpen and Clear Blurry Near Vision for Patients
6.27 May 01, 2017: Visioneering Technologies Expands US Sales Force
6.28 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
6.29 Apr 25, 2017: Essilor International: Revenue increases by 10% Q1 in line with planned 2017 growth trajectory
6.30 Apr 04, 2017: Carl Zeiss Meditec Group achieves first half 2016/17 revenue of approximately EUR 588 million
6.31 Mar 30, 2017: Bausch + Lomb ULTRA For Astigmatism Contact Lenses Introduced
6.32 Mar 27, 2017: Visioneering Technologies Successfully Lists on ASX
6.33 Mar 15, 2017: Bausch + Lomb Introduces Biotrue ONEday For Astigmatism Contact Lenses
6.34 Mar 08, 2017: The KAMRA Corneal Inlay Brings Life Back into Focus for Patients with Presbyopia, Blurring Near Vision
6.35 Mar 03, 2017: Visioneering Technologies Announces Launch of NaturalVue Sphere 1 Day Contact Lenses
6.36 Mar 02, 2017: Johnson & Johnson Vision Expands Portfolio to Reach More Patients with ACUVUE OASYS 1-DAY Brand Contact Lenses for ASTIGMATISM
6.37 Mar 02, 2017: The Cooper Companies Announces First Quarter Results
6.38 Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance
6.39 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
6.40 Feb 17, 2017: Essilor International Reports 2016 Financial Results
6.41 Feb 10, 2017: Carl Zeiss Meditec Off to A Solid Start Into Business Year 2016/17
6.42 Jan 31, 2017: Hoya Announces Third Quarter Financial Results
6.43 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
6.44 Jan 26, 2017: Achievement of sales milestone for COPD products
6.45 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
6.46 Jan 24, 2017: Visioneering Technologies Announces Pam Wyman as Director, Sales Operations & Inside Sales
6.47 Jan 18, 2017: Bausch + Lomb Introduces Zen RC Scleral Contact Lenses
6.48 Jan 17, 2017: Visioneering Technologies Announces Jeff Babbe as New Executive Territory Manager for Chicago, IL
6.49 Jan 11, 2017: Paragon CRT Contact Lenses Approved by China Food & Drug Administration
6.50 Jan 10, 2017: Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA For Presbyopia Contact Lenses
6.51 Jan 10, 2017: Bausch + Lomb ULTRA for Presbyopia Contact Lenses Parameters Expanded
6.52 Jan 10, 2017: Stephen Petranek Appointed to NexOptic Board
6.53 Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors
6.54 Jan 04, 2017: First Contact Lenses Specifically Designed for Digital Lifestyles Makes their CES Debut
6.55 Dec 21, 2016: Visioneering Technologies Announces Brian Atkinson as Territory Manager for the Dallas/Ft. Worth Market
6.56 Dec 13, 2016: Visioneering Technologies Announces Ken Gold as New Executive Territory Manager for the Baltimore-Washington, DC Area
6.57 Dec 12, 2016: Bausch + Lomb Specialty Vision Products Launches New 28 Lens Zenlens Dx Set
6.58 Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology
6.59 Dec 09, 2016: Carl Zeiss Meditec continues its growth trend
6.60 Dec 08, 2016: The Cooper Companies Announces Fourth Quarter and Full Year 2016 Results
6.61 Dec 07, 2016: Essilor Realigns its Organization with its Growing Businesses
6.62 Dec 07, 2016: VTI names executive director of manufacturing and engineering
6.63 Dec 07, 2016: Visioneering Technologies Announces Ms. Rosa Lee as New Executive Director of Manufacturing & Engineering
6.64 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
6.65 Nov 17, 2016: Former Valeant Executive And Former Philidor Ceo Charged In Manhattan Federal Court For Illegal Fraud And Kickback Scheme
6.66 Nov 10, 2016: Alcon introduces new AIR OPTIX plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
6.67 Nov 09, 2016: New Study Shows Groundbreaking Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% Over Two Years
6.68 Nov 09, 2016: Daniel B. Polley, Ph.D., appointed Director of Lauer Tinnitus Research Center at Mass. Eye and Ear
6.69 Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results
6.70 Oct 28, 2016: Hoya Reports Second Quarter Results
6.71 Oct 27, 2016: VTI Introduces the NaturalVue Multifocal QuickStart Calculator
6.72 Oct 26, 2016: Edmund Optics and Varioptic Announce the Availability of the Variable Focus Arctic Liquid Lens in the EO Catalog
6.73 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
6.74 Oct 21, 2016: Essilor: Nine-Month Consolidated Revenue up 7.8% at Constant Exchange Rates
6.75 Oct 13, 2016: Carl Zeiss Meditec appoints Steven C. Schallhorn, MD as Chief Medical Officer
6.76 Oct 12, 2016: Bausch + Lomb Booth to Feature Wet Lab During the Annual Meeting of the American Academy of Ophthalmology in Chicago
6.77 Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer
6.78 Sep 01, 2016: The Cooper Companies CFO Gregory W. Matz to Retire; Albert G. White Named Successor in Planned Transition
6.79 Sep 01, 2016: The Cooper Companies Announces Third Quarter 2016 Results
6.80 Aug 29, 2016: Drug-dispensing contact lens effectively lowers eye pressure in pre-clinical glaucoma model
6.81 Aug 29, 2016: Drug Dispensing Contact lens Effectively Lowers Eye Pressure in Pre clinical Glaucoma Model
6.82 Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer
6.83 Aug 15, 2016: CooperVision Unveils Avaira Vitality Sphere and Toric Two-Week Contact Lenses
6.84 Aug 12, 2016: Carl Zeiss Meditec Grows in Ophthalmology and Microsurgery
6.85 Aug 11, 2016: Outcomes of Presbia Microlens Surgeries in Korean Study Demonstrate Excellent Results
6.86 Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation
6.87 Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results
6.88 Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team
6.89 Aug 01, 2016: Essilor International: Improving Lives by Improving Sight
6.90 Jul 29, 2016: Essilor - First-Half 2016 Results: Revenue Up 8.1% Excluding the Currency Effect
6.91 Jul 29, 2016: Hoya Reports First Quarter Financial Results
6.92 Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors
6.93 Jul 27, 2016: Carl Zeiss Meditec Recruits James V. Mazzo to Lead Its Newly Consolidated Ophthalmology Organization
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Contact Lenses - Pipeline Products by Stage of Development
Table 2: Contact Lenses - Pipeline Products by Segment
Table 3: Contact Lenses - Pipeline Products by Territory
Table 4: Contact Lenses - Pipeline Products by Regulatory Path
Table 5: Contact Lenses - Pipeline Products by Estimated Approval Date
Table 6: Contact Lenses - Ongoing Clinical Trials
Table 7: Contact Lenses Companies - Pipeline Products by Stage of Development
Table 8: Contact Lenses - Pipeline Products by Stage of Development
Table 9: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 10: Biolens - Product Status
Table 11: Biolens - Product Description
Table 12: Contact Lens - Product Status
Table 13: Contact Lens - Product Description
Table 14: Alcon Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 15: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Status
Table 16: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Description
Table 17: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Status
Table 18: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Description
Table 19: Dailies Total 1 Colors SiHy Lens - Product Status
Table 20: Dailies Total 1 Colors SiHy Lens - Product Description
Table 21: Dailies Total 1 Toric SiHy Lens - Product Status
Table 22: Dailies Total 1 Toric SiHy Lens - Product Description
Table 23: Smart Contact Lens - Diabetes - Product Status
Table 24: Smart Contact Lens - Diabetes - Product Description
Table 25: Weekly WG SiHy Lens - Product Status
Table 26: Weekly WG SiHy Lens - Product Description
Table 27: Alcon Laboratories Inc - Ongoing Clinical Trials Overview
Table 28: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Clinical Assessment of a Regimen of AIR OPTIX plus HYDRAGLYDE Silicone Hydrogel Lenses and HYDRAGLYDE Containing Lens Care Solutions
Table 29: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors
Table 30: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors
Table 31: Apeliotus Ophthalmics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Comfort Lens - Product Status
Table 33: Comfort Lens - Product Description
Table 34: Contact Lens - Glaucoma - Product Status
Table 35: Contact Lens - Glaucoma - Product Description
Table 36: Auburn University Pipeline Products & Ongoing Clinical Trials Overview
Table 37: Smart Contact Lenses - Product Status
Table 38: Smart Contact Lenses - Product Description
Table 39: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview
Table 40: MC - PHEMA Based Contact Lens - Product Status
Table 41: MC - PHEMA Based Contact Lens - Product Description
Table 42: Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview
Table 43: Bionic Contact Lens - Product Status
Table 44: Bionic Contact Lens - Product Description
Table 45: Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 46: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Status
Table 47: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Description
Table 48: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Status
Table 49: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Description
Table 50: Ultra Plus Powers Lens - Product Status
Table 51: Ultra Plus Powers Lens - Product Description
Table 52: Ultra Toric Lens - Product Status
Table 53: Ultra Toric Lens - Product Description
Table 54: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
Table 55: Contact Lens Drug Delivery Device - Product Status
Table 56: Contact Lens Drug Delivery Device - Product Description
Table 57: CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Biofinity Energys - Product Status
Table 59: Biofinity Energys - Product Description
Table 60: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Status
Table 61: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Description
Table 62: SiH Multifocal - Product Status
Table 63: SiH Multifocal - Product Description
Table 64: CooperVision Inc - Ongoing Clinical Trials Overview
Table 65: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - A Multi-center Dispensing Clinical Evaluation of MiSight Lenses
Table 66: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Efficacy and Safety of MiSight Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial
Table 67: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 68: EP Global Contact Lens - Product Status
Table 69: EP Global Contact Lens - Product Description
Table 70: Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 71: Drug-Eluting Contact Lenses - Product Status
Table 72: Drug-Eluting Contact Lenses - Product Description
Table 73: e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 74: Electronic Contact Lens - Product Status
Table 75: Electronic Contact Lens - Product Description
Table 76: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview
Table 77: Drug Dispensing Contact Lens - Product Status
Table 78: Drug Dispensing Contact Lens - Product Description
Table 79: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview
Table 80: Hyper-CL - Drug Delivery - Product Status
Table 81: Hyper-CL - Drug Delivery - Product Description
Table 82: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
Table 83: Contact Lens - Product Status
Table 84: Contact Lens - Product Description
Table 85: Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 86: 1-DAY ACUVUE Multifocal Contact Lens - Product Status
Table 87: 1-DAY ACUVUE Multifocal Contact Lens - Product Description
Table 88: Anti-allergic Contact Lens - Product Status
Table 89: Anti-allergic Contact Lens - Product Description
Table 90: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview
Table 91: Therapeutic Contact Lens - Product Status
Table 92: Therapeutic Contact Lens - Product Description
Table 93: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
Table 94: CLM041 - Product Status
Table 95: CLM041 - Product Description
Table 96: Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 97: Contact Lens - Dry Eye Disease - Product Status
Table 98: Contact Lens - Dry Eye Disease - Product Description
Table 99: Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 100: Third PEG Hydrogel Contact Lens - Product Status
Table 101: Third PEG Hydrogel Contact Lens - Product Description
Table 102: Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 103: Presbia Flexivue Microlens - Product Status
Table 104: Presbia Flexivue Microlens - Product Description
Table 105: Presbia Plc - Ongoing Clinical Trials Overview
Table 106: Presbia Flexivue Microlens - Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes
Table 107: RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 108: CLEAr Lens - Product Status
Table 109: CLEAr Lens - Product Description
Table 110: Stanford University Pipeline Products & Ongoing Clinical Trials Overview
Table 111: Polymer Network Hydrogel Contact Lens - Product Status
Table 112: Polymer Network Hydrogel Contact Lens - Product Description
Table 113: SynergEyes Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 114: Duette Progressive With Tangible Hydra-PEG - Product Status
Table 115: Duette Progressive With Tangible Hydra-PEG - Product Description
Table 116: Duette With Tangible Hydra-PEG - Product Status
Table 117: Duette With Tangible Hydra-PEG - Product Description
Table 118: The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview
Table 119: Resonance Circuit Sensor Contact Lens - Product Status
Table 120: Resonance Circuit Sensor Contact Lens - Product Description
Table 121: The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview
Table 122: Stem Cell Contact Lens - Product Status
Table 123: Stem Cell Contact Lens - Product Description
Table 124: UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview
Table 125: Contact Lenses - Product Status
Table 126: Contact Lenses - Product Description
Table 127: University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
Table 128: Aerated Contact Lens - Product Status
Table 129: Aerated Contact Lens - Product Description
Table 130: Telescopic Contact Lens - Product Status
Table 131: Telescopic Contact Lens - Product Description
Table 132: University of Florida Pipeline Products & Ongoing Clinical Trials Overview
Table 133: Vitamin E - Packed Lenses - Product Status
Table 134: Vitamin E - Packed Lenses - Product Description
Table 135: University of Valencia Pipeline Products & Ongoing Clinical Trials Overview
Table 136: Multifocal Contact Lens - Myopia - Product Status
Table 137: Multifocal Contact Lens - Myopia - Product Description
Table 138: Multifocal Contact Lens - Presbyopia - Product Status
Table 139: Multifocal Contact Lens - Presbyopia - Product Description
Table 140: University of Washington Pipeline Products & Ongoing Clinical Trials Overview
Table 141: Bionic Contact Lens - Product Status
Table 142: Bionic Contact Lens - Product Description
Table 143: Solar Powered Augmented Lenses - Product Status
Table 144: Solar Powered Augmented Lenses - Product Description
Table 145: Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 146: Biotrue ONEday Toric Lenses - ASTIGMATISM - Product Status
Table 147: Biotrue ONEday Toric Lenses - ASTIGMATISM - Product Description
Table 148: BLC - 001: SVS - Product Status
Table 149: BLC - 001: SVS - Product Description
Table 150: BLC - 002: SVS - Product Status
Table 151: BLC - 002: SVS - Product Description
Table 152: BLC - 003: SVS/MF/fA - Product Status
Table 153: BLC - 003: SVS/MF/fA - Product Description
Table 154: BLC - 004: Toric - Product Status
Table 155: BLC - 004: Toric - Product Description
Table 156: BLC - 005: SVS/MF - Product Status
Table 157: BLC - 005: SVS/MF - Product Description
Table 158: BLC - 006: SVS - Product Status
Table 159: BLC - 006: SVS - Product Description
Table 160: BLC - 007: MF - Product Status
Table 161: BLC - 007: MF - Product Description
Table 162: BLC - 008: Astigmatism - Product Status
Table 163: BLC - 008: Astigmatism - Product Description
Table 164: BLC - 009: Astigmatism - Product Status
Table 165: BLC - 009: Astigmatism - Product Description
Table 166: XUV - 003: Aphakia - Product Status
Table 167: XUV - 003: Aphakia - Product Description
Table 168: XUV - 004: SVS - Product Status
Table 169: XUV - 004: SVS - Product Description
Table 170: XUV - 007: MF - Product Status
Table 171: XUV - 007: MF - Product Description
Table 172: XUV - 009: SVS - Product Status
Table 173: XUV - 009: SVS - Product Description
Table 174: XUV - 010: Astigmatism - Product Status
Table 175: XUV - 010: Astigmatism - Product Description
Table 176: XUV - 011: MF - Product Status
Table 177: XUV - 011: MF - Product Description
Table 178: XUV - 012: SVS - Product Status
Table 179: XUV - 012: SVS - Product Description
Table 180: XUV - 013: Astigmatism - Product Status
Table 181: XUV - 013: Astigmatism - Product Description
Table 182: XUV - 014: Presbyopia - Product Status
Table 183: XUV - 014: Presbyopia - Product Description
Table 184: XUV - 015: MF - Product Status
Table 185: XUV - 015: MF - Product Description
Table 186: Visioneering Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 187: Contact Lens - Product Status
Table 188: Contact Lens - Product Description
Table 189: NaturalVue (etafilcon A) Sphere 1 Day Contact Lenses - Product Status
Table 190: NaturalVue (etafilcon A) Sphere 1 Day Contact Lenses - Product Description
Table 191: NaturalVue Toric 1 Day Contact Lenses - Product Status
Table 192: NaturalVue Toric 1 Day Contact Lenses - Product Description
Table 193: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Status
Table 194: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Description
Table 195: VTI MPC Lens - Product Status
Table 196: VTI MPC Lens - Product Description
Table 197: VISTAKON Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 198: K-Lens - Product Status
Table 199: K-Lens - Product Description
Table 200: Yolia Health Pipeline Products & Ongoing Clinical Trials Overview
Table 201: TVT Device - Product Status
Table 202: TVT Device - Product Description
Table 203: Glossary
1.2 List of Figures
Figure 1: Contact Lenses - Pipeline Products by Stage of Development
Figure 2: Contact Lenses - Pipeline Products by Segment
Figure 3: Contact Lenses - Pipeline Products by Territory
Figure 4: Contact Lenses - Pipeline Products by Regulatory Path
Figure 5: Contact Lenses - Pipeline Products by Estimated Approval Date
Figure 6: Contact Lenses - Ongoing Clinical Trials

Contact Lenses - Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, “Contact Lenses - Medical Devices Pipeline Assessment, 2017 provides an overview of Contact Lenses currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Contact Lenses pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Contact Lenses under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Contact Lenses and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Contact Lenses under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;